Oncopeptides Presents Promising Data from the Phase 2 ANCHOR Combination Study in Patients With RRMM at ASH Annual Meeting 2019 - Seite 2

The posters are available on the company webpage under:

www.oncopeptides.com / Investor Relations / Presentations / ASH 2019

For more information, please contact:
Jakob Lindberg, CEO of Oncopeptides
E-mail: [e-mail]  
Telephone: [phone]

Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: [e-mail] 
Cell phone: [phone]

The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person above, on December 8, 2019 at 15.00 (CET).

About the OP-104 ANCHOR study
ANCHOR is a phase 1/2 study where melflufen and dexamethasone is dosed in combination with either bortezomib or daratumumab. All patients enrolled must have had 1-4 prior lines of therapy and be refractory (or intolerant) to an immunomodulary agent (IMiD) or a proteasome inhibitor (PI) or both. The enrollment in the daratumumab regimen is completed while recruitment for the bortezomib arm is still ongoing.

More information about the study can be found at:

https://clinicaltrials.gov/ct2/show/NCT03481556?term=melflufen&rank=4

About the OP-102 AL amyloidosis study
The AL amyloidosis study is an Open-label, Phase 1/2 dose-escalation and dose-expansion study of melflufen and dexamethasone in patients with immunoglobulin light chain (AL) amyloidosis following at least one prior line of therapy. The study will enroll approximately 45 patients. The primary endpoint in the phase 2 part is to study the Overall Response Rate (ORR).

More information about the study can be found at:

https://clinicaltrials.gov/ct2/show/NCT04115956?term=melflufen&rank=4

About melflufen
Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload. Peptidases play a key role in protein homeostasis and feature in cellular processes such as cell-cycle progression and programmed cell death. In vitro, melflufen is 50-fold more potent in myeloma cells than the alkylator payload itself due to the increased intracellular alkylator concentration. Melflufen displays cytotoxic activity against myeloma cell lines resistant to other treatments, including alkylators, and has also demonstrated inhibition of DNA repair induction and angiogenesis in preclinical studies.